Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 993
Filter
1.
Diabetes Ther ; 2024 May 14.
Article in English | MEDLINE | ID: mdl-38743307

ABSTRACT

Despite insulin being a lifesaving medication, insulin distress, insulin hesitancy, and insulin inertia remain oft-repeated themes in diabetes discourse. The current model lists three issues: temperament, troublesomeness, and technicality, which contribute to insulin perceptions. Therapeutic patienteducation (TPE), value-added therapy (VAT), and medication counseling are concepts that assist in optimizing insulin perceptions. Insulin icodec is a basal insulin with a half-life of 196 h and a once-weekly or circaseptan frequency of administration. Insulin icodec reduces the frequency of basal insulin administration to one-seventh, which along with the lower requirement of glucose monitoring, reduces the burden of plastic and ancillary supply disposal. Because of its unique frequency of injection, insulin icodec usage requires appropriate counseling and education. This reader-friendly counseling guide helps practitioners offer VAT, as well as TPE while prescribing icodec and other insulins.


Insulin icodec is a newly developed basal insulin that is injected once a week. Specific counseling is required in order to optimize the use of this insulin. We share a 3T model­temperament [of the person], troublesomeness [of the insulin], and technicality [of injection], that influence insulin perceptions. We then use this model to highlight the information that must accompany an insulin icodec prescription, like "value-added therapy". We suggest that as it suits a wide variety of persons living with diabetes, and as its use requires minimal troubleshooting and technical know-how, icodec can be termed a person-friendly insulin. Icodec also reduces the burden of plastic generation and disposal.

2.
Curr Diab Rep ; 24(6): 131-145, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38568467

ABSTRACT

PURPOSE OF REVIEW: Postprandial hyperglycemia, or elevated blood glucose after meals, is associated with the development and progression of various diabetes-related complications. Prandial insulins are designed to replicate the natural insulin release after meals and are highly effective in managing post-meal glucose spikes. Currently, different types of prandial insulins are available such as human regular insulin, rapid-acting analogs, ultra-rapid-acting analogs, and inhaled insulins. Knowledge about diverse landscape of prandial insulin will optimize glycemic management. RECENT FINDINGS: Human regular insulin, identical to insulin produced by the human pancreas, has a slower onset and extended duration, potentially leading to post-meal hyperglycemia and later hypoglycemia. In contrast, rapid-acting analogs, such as lispro, aspart, and glulisine, are new insulin types with amino acid modifications that enhance their subcutaneous absorption, resulting in a faster onset and shorter action duration. Ultra-rapid analogs, like faster aspart and ultra-rapid lispro, offer even shorter onset of action, providing better meal-time flexibility. The Technosphere insulin offers an inhaled route for prandial insulin delivery. The prandial insulins can be incorporated into basal-bolus, basal plus, or prandial-only regimens or delivered through insulin pumps. Human regular insulin, aspart, lispro, and faster aspart are recommended for management of hyperglycemia during pregnancy. Ongoing research is focused on refining prandial insulin replacement and exploring newer delivery methods. The article provides a comprehensive overview of various prandial insulin options and their clinical applications in the management of diabetes.


Subject(s)
Hypoglycemic Agents , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/therapeutic use , Insulin/administration & dosage , Insulin/therapeutic use , Postprandial Period , Hyperglycemia/drug therapy , Female , Blood Glucose/drug effects , Blood Glucose/analysis , Diabetes Mellitus/drug therapy , Pregnancy
3.
J Pak Med Assoc ; 74(3): 589-590, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38591306

ABSTRACT

Psychological well-being is essential for the maintenance of good metabolic health. Modern management of most chronic metabolic disorders rightly focusses on improving the health-related quality of life of persons living with disease. In this brief communication we describe the bidirectional association between muscle function and mood (psychological health), explore the various pathways that link these aspects of health, and underscore their clinical implications. This paper emphasizes the importance of maintaining good mental health through exercise and vice a versa.


Subject(s)
Sarcopenia , Humans , Quality of Life , Brain/diagnostic imaging , Muscle, Skeletal/physiology , Exercise/physiology
4.
J Pak Med Assoc ; 74(3): 591-592, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38591307

ABSTRACT

While diabetes manifests multiple clinical presentations, complications and comorbidities, most modern discourse focuses on the cardiovascular aspects of the syndrome. In this communication, we explore the vast spectrum of fever and diabetes. We highlight the bidirectional interactions between febrile illness and diabetes, as well as drug-drug interactions. These multifaceted connections must be understood by all health care professionals who manage diabetes and/or fever.


Subject(s)
Diabetes Mellitus , Humans , Diabetes Mellitus/epidemiology , Fever/etiology , Comorbidity
5.
J Pak Med Assoc ; 74(3): 593-594, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38591308

ABSTRACT

There is a vast multitude of foodstuffs available, and health care professionals find it challenging to distinguish between healthy and unhealthy offerings. Recent evidence suggests that ultra processed foods should be avoided, as they are associated with harmful effects on health. This communication defines and describes ultra-processed foods, using the internationally accepted NOVA classification. It uses South Asian examples to make the concept easy to understand for South Asian readers.


Subject(s)
Diet , Food, Processed , Humans , Fast Foods/adverse effects , Food Handling , Energy Intake
6.
J Multidiscip Healthc ; 17: 1415-1433, 2024.
Article in English | MEDLINE | ID: mdl-38563041

ABSTRACT

Background: The prevalence of sarcopenia is concerningly high in long-term care settings (LTCS); yet, no exercise programs specifically targeting older adults living in residential care are available. Objective: The goal of the present study was to co-design and validate a program named Reablement Strategies targeting Sarcopenia (ReStart-S) for older long-term care residents. Design: Cross-sectional study with an exploratory phase. Settings: LTCS in Udupi, Karnataka, India. Participants: Sarcopenic older adults diagnosed using Asian Working Group for Sarcopenia 2019 criteria. Material and Methods: The program was designed using a four-step intervention mapping technique involving systematic progression after completing each step. The steps included 1) identifying the appropriate exercise-based intervention for sarcopenia, 2) determining objectives and expected outcomes, 3) seeking expert views through a Delphi consensus approach, and 4) assessing the feasibility of ReStart-S program among older adults living in LTCS. Results: A comprehensive literature review appraised existing exercise programs for managing sarcopenia. A workshop held with six older adults and one caretaker, decided on morning exercise sessions, recommended 2-7 days/week. The results of the review and workshop were compiled for the Delphi process that had seven experts from 5 countries, achieving a 71% response rate after four rounds. In the last step, a pilot study on eight LTCS residents, two males and six females with a mean age of 78.3 ± 8.3 years, was conducted and the program was found to be feasible. Conclusion: The ReStart-S program for managing sarcopenia among older adults residing in LTCS incorporates evidence from the literature and the engagement of older adults, caregivers, and experts, making it a contextually appropriate intervention. Our study also provides researchers and healthcare professionals insight into co-designing an intervention program for vulnerable older adults. Finally, the program evaluation indicates that a full-scale trial testing the efficacy of the ReStart-S program is feasible.

7.
Lung ; 202(2): 151-156, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38461429

ABSTRACT

BACKGROUND: Lung biopsy remains the gold standard in the diagnosis of fibrotic interstitial lung disease (F-ILD), but there is a growing appreciation of the role of pathogenic gene variants in telomere and surfactant protein genes, especially in familial pulmonary fibrosis (FPF). Pleuroparenchymal fibroelastosis (PPFE) is a rare disease that can coexist with different patterns of F-ILD, including FPF. It can be progressive and often leads to respiratory failure and death. This study tested the hypothesis that genetic testing goes beyond radiological and histological findings in PPFE and other F-ILD further informing clinical decision-making for patients and affected family members by identifying pathological gene variants in telomere and surfactant protein genes. METHODS: This is a retrospective review of 70 patients with F-ILD in the setting of FPF or premature lung fibrosis. Six out of 70 patients were diagnosed with PPFE based on radiological or histological characteristics. All patients underwent telomere length evaluation in peripheral blood by Flow-FISH or genetic testing using a customized exome-based panel that included telomere and surfactant protein genes associated with lung fibrosis. RESULTS: Herein, we identified six individuals where radiographic or histopathological analyses of PPFE were linked with telomere biology disorders (TBD) or variants in surfactant protein genes. Each case involved individuals with either personal early-onset lung fibrosis or a family history of the disease. Assessments of telomere length and genetic testing offered insights beyond traditional radiological and histopathological evaluations. CONCLUSION: Detecting anomalies in TBD-related or surfactant protein genes can significantly refine the diagnosis and treatment strategies for individuals with PPFE and other F-ILD.


Subject(s)
Lung Diseases, Interstitial , Pulmonary Fibrosis , Humans , Pulmonary Fibrosis/diagnostic imaging , Pulmonary Fibrosis/genetics , Pulmonary Fibrosis/complications , Tomography, X-Ray Computed/methods , Lung Diseases, Interstitial/diagnosis , Fibrosis , Genetic Testing , Surface-Active Agents , Lung/diagnostic imaging , Lung/pathology
9.
Clin Med Insights Endocrinol Diabetes ; 17: 11795514231203911, 2024.
Article in English | MEDLINE | ID: mdl-38405679

ABSTRACT

Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy. In India, Vildagliptin is commonly prescribed in T2DM patients because it reduces mean amplitude of glycemic excursion (MAGE), has lower risk of hypoglycemia and is weight neutral. Early combination therapy with vildagliptin and metformin is effective and well-tolerated in patients with T2DM, regardless of age or ethnicity. In view of already existing data on vildagliptin and the latest emerging clinical evidence, a group of endocrinologists, diabetologists and cardiologists convened for an expert group meeting to discuss the role and various combinations of vildagliptin in T2DM management. This practical document aims to guide Physicians and Specialists regarding the different available strengths and formulations of vildagliptin for the initiation and intensification of T2DM therapy.

10.
J Pak Med Assoc ; 74(2): 398-399, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38419246

ABSTRACT

Diabetes gastroparesis is a common manifestation of autonomic neuropathy in persons with long-standing, uncontrolled diabetes. Most discussion about its management revolves around the mitigation of symptoms. Here, we share tips on choosing the right glucose-lowering medication, based upon predominant symptomatology of gastroparesis. We highlight about insulin preparations, and their timing of administration, can be tailored according to need. We also emphasize the need to choose oral glucose lowering drugs with care.


Subject(s)
Diabetes Mellitus , Diabetic Neuropathies , Gastroparesis , Humans , Gastroparesis/etiology , Gastroparesis/therapy , Gastroparesis/diagnosis , Diabetic Neuropathies/complications , Diabetic Neuropathies/drug therapy , Glucose , Insulin/therapeutic use , Diabetes Mellitus/drug therapy
11.
J Pak Med Assoc ; 74(2): 400-401, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38419247

ABSTRACT

In this communication, we define and describe gut guardianship as the processes, behaviours and activities that may be followed or undertaken, so as to achieve and maintain a healthy gut, and gut microbiome. These include aspects such related to nutrition, lifestyle, rational drug use, and microbial modulation by using prebiotics and probiotics. Gut guardianship helps in optimizing various aspects of human health including metabolic health, mitogenic balance, micronutrient absorption, mood (gaity) maintenance, gut immunity, and general well-being.


Subject(s)
Gastrointestinal Microbiome , Probiotics , Humans , Prebiotics , Probiotics/therapeutic use , Nutritional Status , Health Status
12.
J Pak Med Assoc ; 74(2): 402-403, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38419248

ABSTRACT

This communication defines and describes the Barocene era, as that phase of human development which is characterized by a major impact of overweight and obesity. We use this term to highlight the fact that overweight and obesity need to be prevented and managed on an urgent footing. If not checked, these endocrine diseases will retard our growth and reduce our well being.


Subject(s)
Obesity , Overweight , Humans , Overweight/prevention & control , Obesity/epidemiology , Obesity/prevention & control
13.
J Neurol ; 271(5): 2547-2559, 2024 May.
Article in English | MEDLINE | ID: mdl-38282082

ABSTRACT

This study aimed to investigate the clinical stratification of amyotrophic lateral sclerosis (ALS) patients in relation to in vivo cerebral degeneration. One hundred forty-nine ALS patients and one hundred forty-four healthy controls (HCs) were recruited from the Canadian ALS Neuroimaging Consortium (CALSNIC). Texture analysis was performed on T1-weighted scans to extract the texture feature "autocorrelation" (autoc), an imaging biomarker of cerebral degeneration. Patients were stratified at baseline into early and advanced disease stages based on criteria adapted from ALS clinical trials and the King's College staging system, as well as into slow and fast progressors (disease progression rates, DPR). Patients had increased autoc in the internal capsule. These changes extended beyond the internal capsule in early-stage patients (clinical trial-based criteria), fast progressors, and in advanced-stage patients (King's staging criteria). Longitudinal increases in autoc were observed in the postcentral gyrus, corticospinal tract, posterior cingulate cortex, and putamen; whereas decreases were observed in corpus callosum, caudate, central opercular cortex, and frontotemporal areas. Both longitudinal increases and decreases of autoc were observed in non-overlapping regions within insula and precentral gyrus. Within-criteria comparisons of autoc revealed more pronounced changes at baseline and longitudinally in early- (clinical trial-based criteria) and advanced-stage (King's staging criteria) patients and fast progressors. In summary, comparative patterns of baseline and longitudinal progression in cerebral degeneration are dependent on sub-group selection criteria, with clinical trial-based stratification insufficiently characterizing disease stage based on pathological cerebral burden.


Subject(s)
Amyotrophic Lateral Sclerosis , Disease Progression , Magnetic Resonance Imaging , Humans , Amyotrophic Lateral Sclerosis/diagnostic imaging , Amyotrophic Lateral Sclerosis/pathology , Male , Female , Middle Aged , Aged , Adult , Brain/diagnostic imaging , Brain/pathology , Severity of Illness Index , Longitudinal Studies , Cerebral Cortex/diagnostic imaging , Cerebral Cortex/pathology
14.
J Peripher Nerv Syst ; 29(1): 28-37, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38268316

ABSTRACT

Peripheral neuropathy (PN) often remains undiagnosed (~80%). Earlier diagnosis of PN may reduce morbidity and enable earlier risk factor reduction to limit disease progression. Diabetic peripheral neuropathy (DPN) is the most common PN and the 10 g monofilament is endorsed as an inexpensive and easily performed test for DPN. However, it only detects patients with advanced neuropathy at high risk of foot ulceration. There are many validated questionnaires to diagnose PN, but they can be time-consuming and have complex scoring systems. Primary care physicians (PCPs) have busy clinics and lack access to a readily available screening method to diagnose PN. They would prefer a short, simple, and accurate tool to screen for PN. Involving the patient in the screening process would not only reduce the time a physician requires to make a diagnosis but would also empower the patient. Following an expert meeting of diabetologists and neurologists from the Middle East, South East Asia and Latin America, a consensus was formulated to help improve the diagnosis of PN in primary care using a simple tool for patients to screen themselves for PN followed by a consultation with the physician to confirm the diagnosis.


Subject(s)
Diabetic Neuropathies , Humans , Diabetic Neuropathies/diagnosis , Risk Factors , Primary Health Care
15.
J Pak Med Assoc ; 74(1): 180-181, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38219186

ABSTRACT

This communication describes a few functional seeds and spices, commonly consumed in South Asia, which may impair the absorption of drugs that are used in diabetes and medical management. The aim of this article is to highlight the possibility of these foods having a 'dysfunctional', rather than functional effect on health. Physicians should include questions about the use of these spices in their history taking.


Subject(s)
Diabetes Mellitus , Functional Food , Humans , Spices/analysis , Seeds
16.
J Pak Med Assoc ; 74(1): 182-184, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38219187

ABSTRACT

Motivation is essential to maintain achieved targets in the long-term management of chronic diseases like obesity. Moreover, the role of motivation becomes even more important when the physiological set point tries to act against the achieved targets. In this brief communication the authors propose a rubric that should assist health care professionals in enhancing the quality of their communication skills, improving the delivery of obesity management, and optimizing therapeutic outcomes by helping their patients with obesity to manage their motivation drive.


Subject(s)
Motivation , Obesity , Humans , Obesity/therapy , Health Personnel , Communication
17.
J Pak Med Assoc ; 74(1): 178-179, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38219196

ABSTRACT

The concepts of sympathy and empathy are well entrenched in social and medical literature. In this article, we explore a relatively less explored construct, compathy. Compathy, defined as feelings that are shared with others, is a higher level of emotional maturity, which helps in achieving better quality care. We propose further discussion and debate on how to measure, attain, and maintain compathy in chronic care practice.


Subject(s)
Emotions , Empathy , Humans , Communication , Patient-Centered Care
19.
Diabetes Ther ; 15(1): 33-60, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37751143

ABSTRACT

INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic became superimposed on the pre-existing obesity and diabetes mellitus (DM) pandemics. Since COVID-19 infection alters the metabolic equilibrium, it may induce pathophysiologic mechanisms that potentiate new-onset DM, and we evaluated this issue. METHOD: A systematic review of the literature published from the 1 January 2020 until the 20 July 2023 was performed (PROSPERO registration number CRD42022341638). We included only full-text articles of both human clinical and randomized controlled trials published in English and enrolling adults (age > 18 years old) with ongoing or preceding COVID-19 in whom hyperglycemia was detected. The search was based on the following criteria: "(new-onset diabetes mellitus OR new-onset DM) AND (COVID-19) AND adults". RESULTS: Articles on MEDLINE (n = 70) and the Web of Science database (n = 16) were included and analyzed by two researchers who selected 20 relevant articles. We found evidence of a bidirectional relationship between COVID-19 and DM. CONCLUSIONS: This link operates as a pathophysiological mechanism supported by epidemiological data and also by the clinical and biological findings obtained from the affected individuals. The COVID-19 pandemic raised the incidence of DM through different pathophysiological and psychosocial factors.

20.
Indian Heart J ; 76 Suppl 1: S80-S82, 2024 Mar.
Article in English | MEDLINE | ID: mdl-37956957

ABSTRACT

Diabetes mellitus is a metabolic disorder that often predisposes to cardiovascular diseases (CVD). CVD is an important cause of morbidity and mortality in diabetes. The typical diabetic dyslipidaemia is characterized by low HDL cholesterol, high triglycerides with mildly increased or even normal LDL. This attenuated rise in LDL is due to the more atherogenic small dense LDL particles. Genetic factors, obesity, lack of physical activity, alcohol abuse, poorly controlled glucose levels are some of the common risk factors for dyslipidaemia. Non-pharmacological management of dyslipidaemia is important and includes modification in the diet, increase in physical activity and efforts to reduce weight. Statins remain the mainstay of pharmacotherapy for dyslipidaemia in diabetes. Due to the small dense LDL, even patients with diabetes who have normal LDL cholesterol, achieve reduction in cardiovascular risk with statin therapy. Those patients who do not achieve acceptable LDL reductions with statin alone can be treated with combination therapy of ezetimibe with statins. Many novel therapies have also emerged such as bempedoic acid and proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors. The targets for LDL cholesterol depend upon the patients underlying cardiovascular risk category. The use of pharmacotherapy for lowering triglycerides in patients with mild to moderate hypertriglyceridemia and diabetes is still a matter of debate. Proper management of dyslipidaemia is critical component of treatment of diabetes mellitus.


Subject(s)
Anticholesteremic Agents , Cardiovascular Diseases , Diabetes Mellitus, Type 2 , Dyslipidemias , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Proprotein Convertase 9/therapeutic use , Diabetes Mellitus, Type 2/complications , Cholesterol, LDL , Dyslipidemias/complications , Dyslipidemias/epidemiology , Dyslipidemias/therapy , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Cardiovascular Diseases/prevention & control , Triglycerides , Anticholesteremic Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...